Author's response to reviews

Title: Keratinocyte growth factor in Acute lung injury to REduce pulmonary dysfunction - a randomised placebo controlled trial (KARE) : study protocol for a randomised controlled trial

Authors:

Laurence JM Cross (ljmcross@msn.com)
Cecilia M O'Kane (c.okane@qub.ac.uk)
Cliona McDowell (cliona.mcdowell@crsc.n-i.nhs.uk)
Jospeh S Elborn (s.elborn@qub.ac.uk)
Michael A Matthy (michael.matthay@ucsf.edu)
Daniel F McAuley (d.f.mcauley@qub.ac.uk)

Version: 3 Date: 17 January 2013

Author's response to reviews: see over
We thank you for your comments in relationship to MS: - 1190089972827328 Keratinocyte growth factor in Acute lung injury to Reduce pulmonary dysfunction – a randomised placebo controlled trial (KARE).

We have submitted a revised manuscript in which the following changes have occurred:

(1) A referenced number has been added, as suggested by the reviewer, to the statement that ALI is a common clinical syndrome.
(2) The word hours has been added as suggested by the reviewer in the section Trial status.
(3) The title has been adjusted to Keratinocyte growth factor in Acute lung injury to Reduce pulmonary dysfunction – a randomised placebo controlled trial (KARE) : study protocol for a randomised controlled trial.
(4) Minor changes to the manuscript has been performed as part of the a further proof reading step identified some typo and grammatical mistakes.
(5) Tables 1 and 2 have been moved to the end of the manuscript as following the guidelines to the Authors.
(6) The statistical analysis plan has been updated and should be presented as a supplementary file.

Yours faithfully,

Danny McAuley